Theranexus is an innovative biopharmaceutical company that spun off from the French Alternative Energies and Atomic Energy Commission (CEA). It specializes in the treatment of rare central nervous system disorders and is a pioneer in the development of drug candidates targeting both neurons and glial cells. Theranexus has a unique advanced therapy candidate identification and characterization platform focused on rare neurological disorders and an initial drug candidate in clinical development for Batten disease.